New Therapeutic Perspectives for Depression: 5-MeO-DMT
New therapies and treatments for depression and other mental health disorders are constantly being researched and developed. One of the most promising avenues currently under investigation is psychotherapy with 5-MeO-DMT, a short-acting psychoactive substance.
Ketamine for Treatment Resistant Depression: Real World Evidence
Treatment-resistant depression affects up to one third of patients with major depressive disorder and is linked to severe impairment and suicide risk. Real-world clinical data show that ketamine offers rapid antidepressant effects, with meaningful symptom reduction in nearly half of treated patients and remission in around one third. Benefits often appear within hours or days and can be maintained over time with follow-up treatment. Evidence also indicates good tolerability, low risk of symptom worsening and effectiveness in both unipolar and bipolar depression.
Microdosing psychedelics: potential benefits and current evidence
Microdosing psychedelics involves taking sub-perceptual doses of substances such as psilocybin or LSD with the aim of improving mood, cognition and emotional wellbeing. This article reviews current scientific evidence on microdosing, including proposed neurobiological mechanisms, potential benefits for depression and anxiety, cognitive and motivational effects, safety considerations and the role of placebo. While observational studies suggest possible benefits, controlled trials show mixed results, highlighting important limitations and the need for further rigorous research before clear clinical recommendations can be made.
Psilocybin and depression
Psilocybin-assisted therapy is emerging as a promising approach for depression, particularly treatment-resistant cases where standard antidepressants show limited efficacy and burdensome side effects. Research suggests psilocybin can produce rapid and sustained reductions in depressive symptoms, partly by enhancing neuroplasticity and facilitating meaningful psychological experiences. When embedded in a structured therapeutic model with preparation, dosing, and integration sessions, psilocybin may foster emotional openness, cognitive flexibility, and long-term positive change, highlighting a potential paradigm shift in how depression is treated within modern clinical research frameworks.
Depression symptoms
Depression, or major depressive disorder, is a common and complex condition marked by persistent low mood, loss of interest, cognitive difficulties and physical symptoms. Diagnosis is usually based on manuals such as the DSM-V by the American Psychiatric Association and the ICD by the World Health Organization, yet many people suffer without fitting rigid criteria. The text explores symptoms, stigma, limits of diagnostic labels and the need for a more holistic, humane approach to mental health care.
Treatment-Resistant Depression: When Nothing Else Works
Treatment-resistant depression occurs when major depressive disorder does not respond to at least two adequate treatments, leading to prolonged suffering and functional impairment. Many patients fail to achieve full remission, despite multiple medication trials, increasing the risk of chronicity and hospitalization. Recent clinical evidence shows ketamine can produce rapid and meaningful symptom reduction in this population, including decreases in suicidal ideation and anxiety. Ongoing and maintenance ketamine sessions may further improve outcomes, offering new hope for patients who have not benefited from conventional antidepressant therapies
Ketamine and depression: the first days of treatment
Depression is a complex disorder affecting mood, cognition, and physical health, and is the leading cause of disability worldwide. Standard treatment combines antidepressant medication and psychotherapy, yet around one third of patients do not respond adequately. This has driven interest in alternatives such as ketamine, a dissociative anesthetic with rapid antidepressant effects. Clinical trials and meta-analyses show symptom improvement within hours and remission in some patients. Ketamine is generally well tolerated and most effective when combined with psychotherapeutic support and careful medical supervision.